To mark Asian American and Pacific Islander Heritage Month, researchers are talking about the need for more studies on the impact of Alzheimer’s.
Translated Doris Molina-Henry, Ph.D., professor of research neurology at the University of Southern California joins Cary to discuss Alzheimer's.
In order to elevate the health within underrepresented groups, there is a call for community participation.
Researchers trying to increase participation from high-risk minority communities
Alzheimer's disease affects millions of people but disproportionately affects Black people. That's why researchers need to diversify their trial pools.
Black adults are twice as likely to develop Alzheimer’s disease as white adults, but they make up fewer than 10% of clinical trial participants, so a new study of a treatment is recruiting diverse candidates of every race and ethnicity.
Dr. Crystal Glover shares how the "AHEAD Study" can help black adults with Alzheimer's
CBS News Bay Area anchor Len Kiese talks to Dr. Doris Molina-Henry, Assistant Professor of Research Neurology at the University of Southern California’s Keck School of Medicine, about how Alzheimer's disease disproportionately affects the African American community
According to the Alzheimer’s Association, older African Americans are twice as likely as their white counterparts to develop Alzheimer’s Disease. In fact, 21.3 percent of Black Americans over the age of 70 are living with the disease.
BOSTON — Two research centers in the Boston area participate in the worldwide “AHEAD Study,” aiming to help prevent Alzheimer’s disease. Researchers are using an experimental drug called BAN 2401 that attacks amyloid plaques that build up in the brain and eventually lead to the devastating disease.
TULSA, Okla. — Central States Research in South Tulsa is participating in the AHEAD Study that aims to help prevent Alzheimer’s disease. Dr. Sarah Land, owner of Central States Research, LLC, says the experimental drug called B-A-N 2-4-0-1 attacks amyloid plaques that build up in the brain and eventually lead to Alzheimer’s. December 30, 2021.
Clinical trials are underway that indicates a blood test can identify a person’s chance of developing brain amyloid, a protein that is a risk factor in Alzheimer’s disease. November 15, 2021
A new blood test may identify more than 80% of people with increased likelihood of having amyloid in the brain, a protein that’s a risk factor for developing Alzheimer’s disease, according to a recent study that was presented this week at Boston’s international Clinical Trials on Alzheimer’s Disease conference. November 12, 2021
New Blood Test to Identify People at Risk of Developing Alzheimer's Symptoms Will Be Used in a Clinical Trial Aiming to Prevent Memory Loss
Research presented today highlights advantage of using blood test for a trial that aims to prevent Alzheimer's. Up to 75 research centers across North America will use blood tests to identify those most at-risk for changes in the brain from Alzheimer's disease, thus, expediting prevention research, November 11, 2021
El Uso de Una Prueba de Sangre en un Ensayo Clínico Dirigido a Prevenir la Pérdida de Memoria, Ayudara a Identificar a Personas en Riesgo de Presentar Síntomas de Enfermedad de Alzheimer
Un estudio presentado hoy resalta las ventajas de utilizar pruebas de sangre para ensayo clínico que busca prevenir el Alzheimer. Hasta 75 centros de investigación de toda Norteamérica utilizarán pruebas de sangre. Las pruebas de sangre servirán para identificar a las personas con mayor riesgo de sufrir cambios en el cerebro debido a la enfermedad de Alzheimer. Se anticipa que este descubrimiento ayudará a acelerar las investigaciones sobre su prevención. November 11, 2021
New research indicates a blood test can be used to identify people with brain amyloid, which is a protein that’s a risk factor for developing Alzheimer’s. November 11, 2021
New clinical trials on memory loss interventions is currently enrolling participants with key Alzhemier’s biomarkers as young as 55 and 60 years old. Tau and beta-amyloid blood test are helping determine who is eligible. November 11, 2021
Dr. Cherian Verghese joined the show to discuss the new AHEAD Study site at Keystone Clinical Studies in Plymouth Meeting, PA and recruit participants as young as 55 years of age. KYW NewsRadio, August 16, 2021
The AHEAD Study team is testing a new investigational treatment, examining whether they can slow or stop the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life. The team is seeking volunteers on its website. KATU 2 Portland, June 15, 2021
Hoag’s Pickup Family Neurosciences Institute in Newport Beach has started the AHEAD Study, which is recruiting people as young as 55 years old who are at risk of developing symptoms of Alzheimer’s as they age. Orange County Register, June 7, 2021
Dr. Reisa Sperling joined the show to recruit participants for the AHEAD Study, a clinical trial that aims to prevent Alzheimer's and create treatments that work for all patients. WDUN Radio, June 3, 2021
The Alzheimer’s Therapeutic Research Institute (ATRI) is seeking volunteers in Imperial County. The Desert Review, June 16, 2021
Individuals between the ages 55-80 who are not currently dealing with memory issues are sought to join the AHEAD Study by participating or volunteering at more than 70 sites across the U.S. and Canada, including Dallas-Fort Worth. News Radio 1080 KRLD, June 3, 2021
Among the top ten causes of death in the United States, Alzheimer's is the only one that cannot be prevented, cured or slowed, but ongoing clinical trials across the country, including at UAB, are working to change that. WVTM NBC 13 Birmingham, May 26, 2021
Researchers at the University of South Florida Byrd Alzheimer's Center and Research Institute are enrolling people for the AHEAD Study. ABC Action News Tampa Bay, March 26, 2021
Improved diagnostics, new ideas for prevention, and perhaps finally a drug for the disease. Boston Globe, October 29, 2020
After cases began emerging worldwide, thousands of clinical trials unrelated to COVID-19 were paused or canceled amid fears that participants would be infected. But now some researchers are finding ways to carry on in spite of the coronavirus. National Public Radio, October 20, 2020.
Researchers at the University of South Florida are participating in a national study to prevent Alzheimer’s before it hits. Tampa Bay Times, September 30, 2020.
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced. September 25, 2020.
An Attleboro man has become the first in the world to take part in groundbreaking Alzheimer's research. WJAR, September 23, 2020.
Kalberer sees himself as a salesman for something that could help millions: participating in Alzheimer’s research. Providence Journal, September 23, 2020.
New study initiated in the U.S. for people who have intermediate or elevated levels of amyloid in their brains. Eisai, July 14, 2020.
Researchers at Butler and Rhode Island Hospitals will participate in a new clinical trial of an antibody that has shown potential to help rid the brain of beta-amyloid, a protein associated with Alzheimer’s disease. Providence Journal, July 14, 2020.